key: cord-0751739-ttecupij
authors: Scollan, Margaret E.; Breneman, Alyssa; Kinariwalla, Neha; Soliman, Yssra; Youssef, Soundos; Bordone, Lindsey A.; Gallitano, Stephanie M.
title: Alopecia Areata After SARS-CoV-2 Vaccination
date: 2021-12-15
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.11.023
sha: 883b03c19c3b602d1c7b87205f43a7234b4eb012
doc_id: 751739
cord_uid: ttecupij

nan

Alopecia areata (AA) is a T-lymphocyte mediated autoimmune condition characterized 65 by hair loss due to an inflammatory response targeting the hair follicle. Recent reports have 66

suggested that COVID-19 may trigger a variety of autoimmune conditions including AA. 1 

Herein, we report nine cases of AA following SARS-CoV-2 vaccination (Table 1, Figure 1 On follow-up exam, decreased hair loss and increased regrowth were noted. The patient elected 76 to begin tofacitinib citrate 5 milligrams (mg) twice a day for further improvement. 77

Case 2: A 57-year-old female with a remote history of AA completed the Pfizer SARS-78

CoV-2 vaccine series in February 2021. Four months later, she experienced substantial hair loss. 79

She attempted trials of compounded tofacitinib 2%, clobetasol 0.05% ointment and clobetasol 80 solution from an outside dermatologist with little improvement. On examination there was 81 widespread non-scarring alopecia of the scalp with foci of hair regrowth. The patient was 82 subsequently started on tofacitinib citrate 5 mg twice a day. vaccination, although they did report one patient with hair loss ten weeks later. 8 Further studies 162 are needed to draw any conclusions regarding the timing between hair loss and vaccination. 163

This report is limited in that none of these cases can be clearly stated as cause and effect. 164

Extensive patient histories were taken to rule out other triggers of AA, such as illnesses or 165 psychological stress, but given the patients' already increased risk of AA from comorbidities 166 and/or family histories, hair loss following vaccination could be coincidental. Further studies are 167 needed to explore the possible role of SARS-CoV-2 vaccination in activation of AA. This report 168

suggests that physicians should have heightened clinical suspicion of SARS-CoV-2 vaccine-169 induced AA one to two months following vaccination after exclusion of other possible triggers. 170

Of note, many medical treatments exist for alopecia, and spontaneous hair regrowth is estimated 171 to occur in approximately eighty percent of patients within a year after the first incidence of hair 172 loss. 9 Indeed, three of our patients had foci of hair regrowth on examination. Overall, this report 173 should not discourage from the overwhelming benefits of SARS-CoV-2 vaccination. 174 175 J o u r n a l P r e -p r o o f Table 1 

Alopecia areata in a 178 patient with SARS-Cov-2 infection

COVID-19: association with rapidly progressive forms of alopecia areata

Public Health Service 183 (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine 184 Adverse Event Reporting System (VAERS)

Recurrence of alopecia areata after covid-19 187 vaccination: A report of three cases in Italy

Alopecia areata after ChAdOx1 190 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor

Alopecia Areata After Vaccination: Recurrence with 193

Alopecia universal en un 195 adulto tras la vacunación de rutina con toxoide tetánico

Hair Loss After Routine Immunizations

Alopecia areata: more than skin deep